Pharmacotherapy of obsessive-compulsive disorder

International Review of Psychiatry

Volumn 9, Issue 1, 1997, Pages 133-148

  Pigott, Teresa A ^a,c   Seay, Sheila ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b University Psychiatric Center   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE;

ADULT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OBSESSION; PRIORITY JOURNAL; REVIEW;

EID: 0030892507     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540269775655     Document Type: Review

References (110)

1. ACKERMAN, D., GREENLAND, S., BYSTRITSKY, A., MORGENSTERN, H. & KATZ, R. (1994). Predictors of treatment response in OCD: multivariate analyses from a multicenter trial of clomipramine. Journal of Clinical Psychopharmacology, 14, 247-254.
2. AMERICAN PSYCHIATRIC ASSOCIATION (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC: American Psychiatric Association.
3. ANANTH, J., SOLYOM, L. & SOLYOM, C. (1975). Doxepin in the treatment of obsessive-compulsive disorder. Psychosomatics, 16, 185-187.
4. ANANTH, J., PECKNOLD, J., VAN DEN STEEN, N. & ENGELSMAN, F. (1981). Double-blind study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuro-psychopharmacology, 5, 257-262.
5. ASBERG, M., THOREN, P. & BERTILSSON, L. (1982). Clomipramine treatment of obsessive-compulsive disorder: biochemical and clinical aspects. Psychopharmacology Bulletin, 18, 13-21.
6. BAER, L. (1994). Factor analysis of symptom subtypes of obsessive-compulsive disorder and their relation to personality and tic disorders. Journal of Clinical Psychiatry, 55, 18-23.
7. BAER, L. & JENIKE, M. (1992). Personality disorders in OCD. Psychiatric Clinics of North America, 15, 803-812.
8. BAER, L., JENIKE, M., BLACK, D., TREECE, C., ROSENFELD, R. & GREIST, J. (1992). Effect of axis II diagnoses on treatment outcome with clomipramine in 54 patients with OCD. Archives of General Psychiatry, 40, 11-18.
9. BARR, L., GOODMAN, W., PRICE, L., MCDOUGLE, C. & CHARNEY, D. (1992). The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies. Journal of Clinical Psychiatry, 53, 17-28.
10. BENFIELD, D., HARRIS, C. & LUSCOMBE, D. (1980). Some psychopharmacological aspects of desmethylclomipramine. Postgraduate Medicine, 56, 13-18.
11. BERGSTROM, R., LEMBERGER, L., FARID, N. & WOLEN, R. (1988). Clinical pharmacology and pharmacokinetics of fluoxetine. British Journal of Psychiatry, 153, 47-53.
12. BISSERBEE, J., WISEMAN, R. & GOLDBERG, M. (1995). Sertraline versus clomipramine in OCD. American Psychiatric Association Annual Meeting, New Research Abstracts, Miami, FL, May 10-15.
13. BROWNE, M., HORN, E. & JONES, T. (1993). The benefits of clomipramine-fluoxetine combination in OCD. Canadian Journal of Psychiatry, 38, 242-243.
14. CARRASCO, J., HOLLANDER, E., SCHNEIER, F. & LIEBOWITZ, M. (1992). Treatment outcome of OCD with comorbid social phobia. Journal of Clinical Psychiatry, 53, 387-391.
15. CASAS, M., ALVAREZ, E. & CURO, P. (1986). Cyproterone acetate for treatment-resistant obsessive-compulsive neurosis. Acta Psychiatrica Scandinavica, 73, 221-222.
16. CHOUINARD, G., BELANGER, M. & SULTAN, S. (1995). Potentiation of fluoxetine by aminoglutethimide steroid suppression in OCD. American Psychiatric Association Annual Meeting, New Research Abstracts, Miami, FL, May 10-15.
17. CLOMIPRAMINE COLLABORATIVE STUDY GROUP (1991). Clomipramine in the treatment of patients with OCD. Archives of General Psychiatry, 48, 730-738.
18. CUSACK, B., NELSON, A. & RICHELSON, E. (1994). Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology, 114, 559-565.
19. DELTITO, J. (1994). Valproate pretreatment for the difficult to treat patient with OCD. Journal of Clinical Psychiatry, 55, 500.
20. DEVANE, C. (1992). Pharmacokinetics of the selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 53, 13-20.
21. DEVANE, C. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55, 38-45.
22. DEVEAUGH-GEISS, J., KATZ, R., LANDAU, P., GOODMAN, W. & RASMUSSEN, S. (1990). Clinical predictors of treatment response in OCD: exploratory analyses from multi-center trials of clomipramine. Psychopharmacology Bulletin, 26, 54-59.
23. DUPONT, R. & RICE, D. (1994). Economic cost of OCD. Journal of American Medical Association, 42, 23-26.
24. EISEN, J., RASMUSSEN, S., PHILLIPS, K., LYDIARD, R. & PIGOTT, T. A. (1995). Degree of conviction and treatment response in OCD. American Psychiatric Association Annual Meeting, New Research Abstracts, Miami, FL, May 10-15.
25. FLAMENT, M., RAPAPORT, J., MURPHY, D., LAKE, C. & BERG, C. (1987). Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Archives of General Psychiatry, 44, 219-225.
26. FONTAINE, R. & CHOUINARD, G. (1989). Fluoxetine in the long-term maintenance treatment of OCD. Psychiatric Annals, 19, 88-91.
27. FREEMAN, C., TRIMBLE, M., DEAKIN, J., STOKES, T. & ASHFORD, J. (1994). Fluvoxamine versus clomipramine in the treatment of OCD: a multi-center, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry, 55, 301-305.
28. FRENKEL, A., ROSENTHAL, J., NEZRIGLU, A. & WINSTON, A. (1990). Efficacy of long-term treatment of OCD. Mt. Sinai Journal of Medicine, 57, 23-32.
29. GOODMAN, W. K., PRICE, L. H., RASMUSSEN, S. A., MAZURE, C., DELGADO, P., HENINGER, G. R. & CHARNEY, D. S. (1989a). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006-1011.
30. GOODMAN, W., PRICE, L., RASMUSSEN, S., MAZURE, C., DELGADO, P., HENINGER, G. & CHARNEY, D. (1989b). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). II. Validity. Archives of General Psychiatry, 46, 1012-1016.
31. GOODMAN, W., RASMUSSEN, S. & PRICE, L. (1989c). Predictors of response to clomipramine. American College of Neuropharmacology Annual Meeting, New Research Abstracts, Miami, FL, May 10-15.
32. GOODMAN, W., MCDOUGLE, C., PRICE, L., RIDDLE, M., PAULS, D. & LECKMAN, J. (1990). Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? Journal of Clinical Psychiatry, 51, 36-43.
33. GOODMAN, W., MCDOUGLE, C. & PRICE, L. (1992). Pharmacotherapy of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 53, 29-37.
34. GOODMAN, W., MCDOUGLE, C., BARR, L. & PRICE, L. (1993). Biological approaches to the treatment-refractory patient. 1st International OCD Conference Abstracts, Isle of Capri, March 10-15.
35. GRADY, T. A., PIGOTT, T. A., L'HEUREUX, F., HILL, J. L., BERNSTEIN, S. E. & MURPHY, D. L. (1993). A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. American Journal of Psychiatry, 150, 819-821.
36. GREIST, J., JEFFERSON, J., KOBACK, K., KATZELNICK, D. & SERLIN, R. (1995a). Efficacy and tolerability of serotonin inhibitors in obsessive-compulsive disorder: a meta-analysis. Archives of General Psychiatry, 52, 53-60.
37. GREIST, J., CHOUINARD, G. & DUBOFF, E. (1995b). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with OCD. Archives of General Psychiatry, 51, 559-567.
38. HALL, H. & OGREN, S. (1984). Effects of antidepressant drugs on histamine-H-sub-1 receptors in the brain. Life Sciences, 34, 597-605.
39. HALL, H., SALLEMARK, M. & WEDEL, I. (1984). Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacologica and Toxicology, 54, 379-384.
40. HERMESH, H., AIZENBERG, D. & MUNITZ, H. (1990). Trazodone treatment in clomipramine-resistant OCD. Clinical Neuropharmacology, 13, 322-328.
41. HEWLETT, W., VINOGRADOV, S. & AGRAS, W. (1992). Clomipramine, clonazepam, and clonidine treatment of OCD. Journal of Clinical Psychopharmacology, 12, 420-430.
42. HOLLANDER, E. & LIEBOWITZ, M. (1988). Augmentation of antiobsessional treatment with fenfluramine. American Journal of Psychiatry, 145, 1314-1315.
43. HOLLANDER, E., FAY, M. & LIEBOWITZ, M. (1988). Clonidine and clomipramine in OCD. American Journal of Psychiatry, 145, 388-389.
44. HOLLANDER, E., SCHIFFMAN, E., COHEN, B., RIVER STEIN, A., ROSEN, W., GORMAN, J., FYER, A., PAPP, L. & LIEBOWITZ, M. (1990a). Signs of central nervous system dysfunction in obsessive-compulsive disorder. Archives of General Psychiatry, 48, 278-279.
45. HOLLANDER, E., DECARIA, C., SCHNEIER, F., LIEBOWITZ, M. & KLEIN, D. (1990b). Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry, 51, 119-123.
46. HYTTEL, J. (1993). Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nordic Journal of Psychiatry, 47, 5-12.
47. INSEL, T., MURPHY, D. L., COHEN, R., ALTERMAN, I., KILTS, C. & LINNOILA, M. (1983). OCD: a double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry, 40, 605-612.
48. INSEL, T., MUELLER, E., ALTERMAN, I., LINNOILA, M. & MURPHY, D. L. (1985). Obsessive-compulsive disorder and serotonin: is there a connection? Biological Psychiatry, 20, 1174-1188.
49. JAIN, V., SWINSON, R. & THOMAS, J. (1970). Phenelzine in obsessional neurosis. British Journal of Psychiatry, 117, 237-238.
50. JANICAK, P., DAVIS, J., PRESKORN, S. & AYD, F. (1993). Principles and practice of psychopharmacotherapy (pp. 209-288). Philadelphia, PA: Williams & Wilkins, Inc.
51. JENIKE, M. (1982). Use of monoamine oxidase inhibitors in OCD. British Journal of Psychiatry, 140, 159.
52. JENIKE, M. (1992). Pharmacologic treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America, 15, 895-919.
53. JENIKE, M. & BAER, L. (1988). Buspirone in OCD: an open trial. American Journal of Psychiatry, 145, 1285-1286.
54. JENIKE, M. & RAUSH, S. (1994). Managing the patient with treatment-resistant obsessive-compulsive disorder: current strategies. Journal of Clinical Psychiatry, 55, 11-17.
55. JENIKE, M., SURNAM, O., CASSEM, N., ZUSKY, P. & ANDERSON, W. (1983). Monoamine oxidase inhibitors in OCD. Journal of Clinical Psychiatry, 44, 131-132.
56. JENIKE, M., BAER, L., MINICHIELLO, W., SCHWARTZ, C. & CAREY, R. (1986). Concomitant obsessive-compulsive disorder and schizotypal personality disorder. American Journal of Psychiatry, 143, 530-533.
57. JENIKE, M., HYMAN, S., BAER, L., HOLLAND, A., MINICHIELLO, W., BUTTOLPH, L., SUMMERGRAD, P., SEYMOUR, R. & RICCIARDI, J. (1989). A controlled trial of fluvoxamine in OCD: implications for a serotonergic theory. American Journal of Psychiatry, 147, 1209-1215.
58. JENIKE, M. A., BAER, L. & GREIST, J. H. (1990). Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. Journal of Clinical Psychopharmacology, 10, 122-124.
59. JENIKE, M., BAER, L. & BUTTOLPH, L. (1991). Buspirone augmentation of fluoxetine in patients with OCD. Journal of Clinical Psychiatry, 1, 13-14.
60. KASVIKIS, Y. & MARKS, I. (1988). Clomipramine in obsessive-compulsive ritualizers treated with exposure therapy: relations between dose, plasma levels, outcome, and side effects. Psychopharmacology, 95, 25-34.
61. KORAN, L. (1995). Sertraline versus clomipramine in OCD. Annual Meeting of the American Psychiatric Association, New Research Abstracts, Miami, FL, May 10-15.
62. LECKMAN, J., WALKER, D., GOODMAN, W., RASMUSSEN, S., PAULS, D. & COHEN, D. (1993). Just right perceptions associated with compulsive behavior in Tourette's Syndrome and OCD. 1st International OCD Conference Abstracts, Isle of Capri, March 10-15.
63. LEONARD, H., SWEDO, S., LENANE, M., RETTEW, D., CHESLOW, D., HAMBURGER, S. & RAPOPORT, J. (1991). A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 48, 922-927.
64. LEVINE, R., HOFFMAN, J., KNEPPLE, E. & KENIN, M. (1989). Long-term fluoxetine treatment of a large number of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 9, 281-283.
65. LIPSEDGE, M. & PROTHERO, W. (1987). Clonidine and clomipramine in OCD. American Journal of Psychiatry, 144, 965-966.
66. MARKOVITZ, P., STAGNO, S. & CALABRESE, J. (1990). Buspirone treatment of fluoxetine in OCD. American Journal of Psychiatry, 147, 798-800.
67. MAVISSAKALIAN, M., TURNER, S., MICHELSON, L. & JACOB, R. (1985). Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? American Journal of Psychiatry, 142, 572.
68. MAVISSAKALIAN, M., JONES, B., OLSEN, S. & PEREL, J. (1990). Clomipramine in obessive-compulsive disorder: clinical response and plasma level. Journal of Clinical Psychopharmacology, 5, 207-212.
69. MCDOUGLE, C., PRICE, L., GOODMAN, W., CHARNEY, D. & HENINGER, G. (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175-184.
70. MCDOUGLE, C., GOODMAN, W., LECKMAN, J., HOLZER, C., BARR, L., MCCANCE-KATZ, E., HENINGER, G. & PRICE, L. (1993). Limited therapeutic effect of the addition of buspirone in fluvoxamine-refractory OCD. American Journal of Psychiatry, 150, 647-649.
71. MCDOUGLE, C., GOODMAN, W., LECKMAN, J., LEE, N., HENINGER, G. & PRICE, L. (1994). Halperidol addition in fluvoxamine-refractory obsessive-compulsiver disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302-308.
72. MONTGOMERY, S., BULLOCK, T., FINEBERG, N. & MONTGOMERY, D. (1992). Selective serotonin reuptake inhibitors in OCD. Clinical Neuropharmacology, 15, 255-256.
73. MONTGOMERY, S., MCINTYRE, A., OSTERHEIDER, M., SARTESCHI, P., ZITTERL, W., ZOHAR, J., BIRKETT, M. & WOOD, A. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R OCD. European Neuropsychopharmacohgy, 3, 143-152.
74. MURPHY, D. L. & PIGOTT, T. A. (1990). A comparative examination of a role for serotonin in obsessive-compulsive disorder, panic disorder, and anxiety. Journal of Clinical Psychiatry, 51, 53-58.
75. NIRENBERG, A. & COLE, J. (1992). Antidepressant adverse drug reactions. Journal of Clinical Psychiatry, 52, 40-47.
76. PATO, M., ZOHAR-KADOUCH, R., ZOHAR, J. & MURPHY, D. L. (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. American Journal of Psychiatry, 145, 1521-1525.
77. PATO, M., HILL, J. & MURPHY, D. L. (1990). A clomipramine dosage reduction study in the course of long-term treatment of OCD patients. Psychopharmacology Bulletin, 26, 211-214.
78. PATO, M. T., PIGOTT, T. A., HILL, J. L., GROVER, G. N., BERNSTEIN, S. E. & MURPHY, D. L. (1991). Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry, 148, 127-129.
79. PICCINELLI, M., PINI, S., BELLANTUONO, C. & WILKINSON, G. (1995). Efficacy of drug treatment in OCD. A meta-analytic review. British Journal of Psychiatry, 166, 424-443.
80. PIGOTT, T. A. (1996). Where the serotonin-selectivity story begins. Journal of Clinical Psychiatry, 57, 11-20.
81. PIGOTT, T. A., PATO, M. T., BERNSTEIN, S. E., GROVER, G. N., HILL, J. L., TOLLIVER, T. J. & MURPHY, D. L. (1990). Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 47, 1543-1550.
82. PIGOTT, T. A., PATO, M. T., L'HEUREUX, F., HILL, J. L., GROVER, G. N., BERNSTEIN, S. E. & MURPHY, D. L. (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated OCD patients. Journal of Clinical Psychopharmacology, 11, 242-248.
83. PIGOTT, T. A., L'HEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E. & MURPHY, D. L. (1992a). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated OCD patients. Journal of Clinical Psychopharmacology, 12, 11-18.
84. PIGOTT, T. A., L'HEUREUX, F., BERNSTEIN, S., RUBINSTEIN, C., DUBBERT, B. & MURPHY, D. L. (1992b). Controlled study of clonazepam augmentation in clomipramine- or fluoxetine-treated patients with OCD. 145th Annual American Psychiatric Association Meeting, New Research Abstracts, Washington DC, May 20-24.
85. PIGOTT, T. A., L'HEUREUX, F., RUBENSTEIN, C. S., BERNSTEIN, S. E., HILL, J. L. & MURPHY, D. L. (1992c). A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12, 156-162.
86. PIGOTT, T. A., L'HEUREUX, F. & MURPHY, D. L. (1993). Pharmacological approaches to treatment-resistant OCD patients. 1st International OCD Conference Abstracts, Isle of Capri, March 10-15.
87. PIGOTT, T. A., L'HEUREUX, F., DUBBERT, B., BERNSTEIN, S. & MURPHY, D. L. (1994). Obsessive-compulsive disorder: comorbid conditions. Journal of Clinical Psychiatry, 55, 15-27.
88. PIGOTT, T. A., DUBBERT, B., L'HEUREUX, F., CANTER, S. & MURPHY, D. L. (1996). In M. MAVISSAKALIAN & R. PRIOR (Eds), Long-term treatment of anxiety disorders. New York: Elsevier.
89. PRESKORN, S. (1996). Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications, Inc.
90. RASMUSSEN, S. (1984). Lithium and tryptophan augmentation in clomipramine-resistant OCD. American Journal of Psychiatry, 141, 1283-1285.
91. RASMUSSEN, S. & EISEN, J. (1992). The epidemiology and differential diagnosis of OCD. Journal of Clinical Psychiatry, 53 (Suppl.), 4-10.
92. RASMUSSEN, S., EISEN, J. & PATO, M. (1993). Current issues in the pharmacologic management of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 54, 4-9.
93. RASMUSSEN, S., GOODMAN, W., GREIST, J., JENIKE, M. & KOZAK, M. (1996). Fluvoxamine in the treatment of OCD: a multi-center double-blind, placebo-controlled study in outpatients. American Journal of Psychiatry (in press).
94. RICHELSON, E. (1994). Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clinical Proceedings, 69, 1069-1081.
95. SIMEON, J., THATTE, S. & WIGGINS, D. (1990). Treatment of adolescent OCD with a clomipramine-fluoxetine combination. Psychopharmacology Bulletin, 26, 285-290.
96. SMERALDI, E., ERZEGOVESI, S. & BIANCHI, I. (1992). Fluvoxamine versus clomipramine treatment in OCD: a preliminary study. New Trends in Experimental and Clinical Psychiatry, 8, 63-65.
97. STEINER, M., BUSHNELL, W., GERGEL, I. & WHEADON, D. (1995). Long-term treatment with paroxetine of outpatients with OCD: an extension of the fixed dose study. American Psychiatric Association Annual Meeting, New Research Abstracts, Miami, FL, May 9-12.
98. STERN, R., MARKS, I. & WRIGHT, J. (1980). Clomipramine: plasma levels, side effects, and outcome in obsessive-compulsive neurosis. Journal of Postgraduate Medicine, 56, 134-139.
99. THOREN, P., ASBERG, M., BERTELSSON, L., MELLSTROM, B., SJOGVIST, F. & TRASKMAN, L. (1980a). Clomipramine treatment of OCD. II: Biochemical aspects. Archives of General Psychiatry, 37, 1289-1294.
100. THOREN, P., ASBERG, M., CROHNHOLM, B., JORNESTEDT, L. & TRACHMAN, L. (1980b). Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Archives of General Psychiatry, 37, 1281-1285.
101. TOLLEFSON, G., RAMPEY, A., POTVIN, J., JENIKE, M., RUSH, A. DOMINGUEZ, R., KORAN, L., SHEAR, M., GOODMAN, W. & GENDUSO, L. (1994a). A multi-center investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51, 559-567.
102. TOLLEFSON, G., BIRKETT, M., KORAN, L. & GENDUSO, L. (1994b). Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Journal of Clinical Psychiatry, 55, 69-78.
103. VALLEJO, J., OLIVARES, J., MARCOS, T., BULBENA, A. A. & MENCHON, J. (1992). Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. British Journal of Psychiatry, 161, 665-670.
104. VOLAVKA, J., NEZIROGLU, F. & YARYURA-TOBIAS, J. (1985). Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Research, 14, 85-93.
105. WALLINDER, J., SKOTT, A., CARLSON, A., NAGY, A. & BJORNERIK, R. (1976). Potentiation of the anti-depressant action of clomipramine by tryptophan. Archives of General Psychiatry, 33, 1384-1389.
106. WEISSMAN, M., BLAND, R., CANINO, G., GREENWALD, S., HWU, H., LEE, C., NEWMAN, S., OAKLEY-BROWNE, M., RUBIO-STIPEC, M., WICKRAMARATNE, P., WITTCHEN, H. & YEH, E. (1994). The cross national epidemiology of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 55, 5-10.
107. WHEADON, D., BUSHNELL, W. & STEINER, M. (1993). A fixed-dose comparison of 20, 40 or 60 mg of paroxetine to placebo in the treatment of OCD. American College of Neuropharmacology Annual Meeting, Honolulu, HI, Dec 13-17.
108. YARYURA-TOBIAS, J. & BHAGAVAN, H. (1977). L-tryptophan in OCD. American Journal of Psychiatry, 134, 1298-1299.
109. ZOHAR, J. & INSEL, T. (1987). Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry, 22, 667-687.
110. ZOHAR, J. & JUDGE, R. (1995). Paroxetine versus clomipramine in the treatment of OCD. British Journal of Psychiatry (submitted).